Balanced polymorphism selected by genetic versus infectious human disease

Annual Review of Genomics and Human Genetics

Volumn 3, Issue , 2002, Pages 263-292

  Dean, Michael ^a   Carrington, Mary ^a   O'Brien, Stephen J ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

Chemokine receptors; HIV 1; HLA; Infection

Indexed keywords

CHEMOKINE RECEPTOR; HLA ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE RESISTANCE; DNA POLYMORPHISM; EPIDEMIC; GENE CLUSTER; GENE MUTATION; GENETIC DISORDER; GENETIC ORGANIZATION; GENOME ANALYSIS; HLA SYSTEM; HOST RESISTANCE; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENETICS; INFECTION; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ALLELES; CHEMOKINES; COMMUNICABLE DISEASES; CYSTIC FIBROSIS; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HETEROZYGOTE; HUMANS; MALARIA; MODELS, GENETIC; PEDIGREE; POLYMORPHISM, GENETIC; RECEPTORS, CHEMOKINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036403768     PISSN: 15278204     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.genom.3.022502.103149     Document Type: Review

References (153)

1. Adams RJ. 1995. Sickle cell disease and stroke. J. Child Neurol. 10:75-76
2. Alric L, Fort M, Izopet J, Vinel JP, Charlet JP, et al. 1997. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 113:1675-81
3. Angelicheva D, Boteva K, Jordanova A, Savov A, Kufardjieva A, et al. 1994. Cystic fibrosis patients from the Black Sea region: The 1677delTA mutation. Hum. Mutat. 3:353-57
4. Ansari-Lari MA, Liu XM, Metzker ML, Rut AR, Gibbs RA. 1997. The extent of genetic variation in the CCR5 gene. Nat. Genet. 16:221-22
5. Balashov KE, Rottman JB, Weiner HL, Hancock WW. 1999. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. USA 96:6873-78
6. Barcellos LF, Schito AM, Rimmler JB, Vittinghoff E, Shih A, et al. 2000. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics 51:281-88
7. Barrett S, Ryan E, Crowe J. 1999. Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J. Hepatol. 30:979-83
8. Beck S, Trowsdale J. 2000. The human major histocompatibility complex: Lessons from the DNA sequence. Annu. Rev. Genomics Hum. Genet. 1:117-37
9. Bennetts BH, Teutsch SM, Buhler MM, Heard RN, Stewart GJ. 1997. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum. Immunol. 58:52-59
10. Berger EA, Murphy PM, Farber JM. 1999. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700
11. Black FL. 1992. Why did they die? Science 258:1739-40
12. Black FL, Hedrick PW. 1997. Strong balancing selection at HLA loci: Evidence from segregation in South Amerindian families. Proc. Natl. Acad. Sci. USA 94:12452-56
13. Blanpain C, Lee B, Tackoen M, Puffer B, Boom A, et al. 2000. Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood 96:1638-45
14. Boring L, Gosling J, Monteclaro FS, Lusis AJ, Tsou CL, Charo IF. 1996. Molecular cloning and functional expression of murine JE (monocyte chemoattractant protein 1) and murine macrophage inflammatory protein lalpha receptors: Evidence for two closely linked C-C chemokine receptors on chromosome 9. J. Biol. Chem. 271:7551-58
15. Bothamley GH, Beck JS, Schreuder GM, D'Amaro J, de Vries RR, et al. 1989. Association of tuberculosis and M. tuberculosis-specific antibody levels with HLA. J. Infect. Dis. 159:549-55
16. Brahmajothi V, Pitchappan RM, Kakkanaiah VN, Sashidhar M, Rajaram K, et al. 1991. Association of pulmonary tuberculosis and HLA in South India. Tuber 72:123-32
17. Bream JH, Young HA, Rice N, Martin MP, Carrington M, O'Brien SJ. 1999. CCR5 promoter alleles and specific DNA binding factors. Science 284:223a
18. Cairns JS, D'Souza MP. 1998. Chemokines and HIV-1 second receptors: The therapeutic connection. Nat. Med. 4:563-68
19. Carrington M, Kissner T, Gerrard B, Ivanov S, O'Brien SJ, Dean M. 1997. Novel alleles of the chemokine-receptor gene CCR5. Am. J. Hum. Genet. 61:1261-67
20. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, et al. 1999. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage. Science 283:1748-52
21. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR. 1994. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl. Acad. Sci. USA 91:2752-56
22. Chaudhuri A, Polyakova J, Zbrzezna V, Pogo AO. 1995. The coding sequence of Duffy blood group gene in humans and simians: Restriction fragment length polymorphism, antibody and malarial parasite specificities, and expression in nonerythroid tissues in Duffy-negative individuals. Blood 85:615-21
23. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, et al. 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-48
24. Craggs A, Welfare M, Donaldson PT, Mansfield JC. 2001. The CC chemokine receptor 5-delta32 mutation is not associated with inflammatory bowel disease (IBD) in NE England. Genes Immun. 2:114-16
25. Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R, Donaldson PT. 1998. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J. Hepatol. 29:207-13
26. Cuthbert AW, Halstead J, Ratcliff R, Colledge WH, Evans MJ. 1995. The genetic advantage hypothesis in cystic fibrosis heterozygotes: A murine study. J. Physiol. (London) 482:449-54
27. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, et al. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273:1856-62
28. del Guercio MF, Sidney J, Hermanson G, Perez C, Grey HM, et al. 1995. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J. Immunol. 154:685-93
29. Deng HK, Unutmaz D, Kewal-Ramani VN, Littman DR. 1997. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 388:296-300
30. Diamond J. 1991. Curse and blessing of the ghetto. Discover 12:60-65
31. Doherty PC, Zinkernagel RM. 1975. Enhanced immunological surveillance in mice heterozygous at the H-2 gene complex. Nature 256:50-52
32. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, et al. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149-58
33. Estivill X, Bancells C, Ramos C. 1997. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. Hum. Mutat. 10:135-54
34. Evans DT, Piekarczyk MS, Allen TM, Boyson JE, Yeager M, et al. 1997. Immunodominance of a single CTL epitope in a primate species with limited MHC class I polymorphism. J. Immunol. 159:1374-82
35. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, et al. 2000. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 287:2274-77
36. Flint J, Hill AV, Bowden DK, Oppenheimer SJ, Sill PR, et al. 1986. High frequencies of alpha-thalassaemia are the result of natural selection by malaria. Nature 321:744-50
37. Friedman MJ, Trager W. 1981. The biochemistry of resistance to malaria. Sci. Am. 244:154-55, 158-64
38. Gabriel SE, Clarke LL, Boucher RC, Stutts MJ. 1993. CFTR and outward rectifying chloride channels are distinct proteins with a regulatory relationship. Nature 363:263-68
39. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, et al. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes. Nature 397:436-41
40. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, et al. 2001. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344:1668-75
41. Garred P, Madsen HO, Petersen J, Marquart H, Hansen TM, et al. 1998. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J. Rheumatol. 25:1462-65
42. Garzino-Demo A, DeVico AL, Conant KE, Gallo RC. 2000. The role of chemokines in human immunodeficiency virus infection. Immunol. Rev. 177:79-87
43. Girardet A, McPeek MS, Leeflang EP, Munier F, Amheim N, et al. 2000. Meiotic segregation analysis of RB1 alleles in retinoblastoma pedigrees by use of single-sperm typing. Am. J. Hum. Genet. 66:167-75
44. Gomez-Reino JJ, Pablos JL, Carreira PE, Santiago B, Serrano L, et al. 1999. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum. 42:989-92
45. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, et al. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3:212-17
46. Grebner EE, Tomczak J. 1991. Distribution of three alpha-chain betahexosaminidase A mutations among Tay-Sachs carriers. Am. J. Hum. Genet. 48:604-7
47. Guignard F, Combadiere C, Tiffany HL, Murphy PM. 1998. Gene organization and promoter function for CC chemokine receptor 5 (CCR5). J. Immunol. 160:985-92
48. Hadley TJ, Peiper SC. 1997. From malaria to chemokine receptor: The emerging physiologic role of the Duffy blood group antigen. Blood 89:3077-91
49. Haldane JBS. 1949. Disease and evolution. Ric. Sci. Suppl. 19:2-11
50. Hall IP, Wheatley A, Christie G, McDougall C, Hubbard R, Helms PJ. 1999. Association of CCR5 delta32 with reduced risk of asthma. Lancet 354:1264-65
51. Hedrick PW, Thomson G. 1983. Evidence for balancing selection at HLA. Genetics 104:449-56
52. Hedrick PW, Whittam TS, Parham P. 1991. Heterozygosity at individual amino acid sites: Extremely high levels for HLA-A and -B genes. Proc. Natl. Acad. Sci. USA 88:5897-901
53. Herrick JB. 1910. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch. Intern. Med. 6:517-21
54. Hill AV. 1998. The immunogenetics of human infectious diseases. Annu. Rev. Immunol. 16:593-617
55. Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, et al. 1991. Common West African HLA antigens are associated with protection from severe malaria. Nature 352:595-600
56. Hogenauer C, Santa Ana CA, Porter JL, Millard M, Gelfand A, et al. 2000. Active intestinal chloride secretion in human carriers of cystic fibrosis mutations: An evaluation of the hypothesis that heterozygotes have subnormal active intestinal chloride secretion. Am. J. Hum. Genet. 67:1422-27
57. Hohler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, et al. 1997. HLADRB1*1301 and *1302 protect against chronic hepatitis B. J. Hepatol. 26:503-7
58. Howard OM, Shirakawa AK, Turpin JA, Maynard A, Tobin GJ, et al. 1999. Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 Co-receptor and ligand binding function. J. Biol. Chem. 274:16228-34
59. Hughes AL, Nei M. 1988. Pattern of nucleotide substitution at major histocompatibility complex class I loci reveals overdominant selection. Nature 335:167-70
60. Hughes AL, Nei M. 1989. Nucleotide substitution at major histocompatibility complex class II loci: Evidence for overdominant selection. Proc. Natl. Acad. Sci. USA 86:958-62
61. Hughes AL, Yeager M. 1998. Natural selection at major histocompatibility complex loci of vertebrates. Annu. Rev. Genet. 32:415-35
62. Ingram VM. 1959. A specific elemental difference between the globins of normal and sickle cell anemia hemoglobins. Nature 178:792-94
63. Itescu S, Mathur-Wagh U, Skovron ML, Brancato LJ, Marmor M, et al. 1992. HLA-B35 is associated with accelerated progression to AIDS. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 5:37-45
64. Jeffery KJ, Usuku K, Hall SE, Matsumoto W, Taylor GP, et al. 1999. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc. Natl. Acad. Sci. USA 96:3848-53
65. Johnson RP, Trocha A, Buchanan TM, Walker BD. 1993. Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone. J. Virol. 67:438-45
66. Just JJ. 1995. Genetic predisposition to HIV-1 infection and acquired immune deficiency virus syndrome: A review of the literature examining associations with HLA [corrected]. Hum. Immunol. 44:156-69
67. Kalman YM, Kerem E, Darvasi A, DeMarchi J, Kerem B. 1994. Difference in frequencies of the cystic fibrosis alleles, delta F508 and W1282X, between carriers and patients. Eur. J. Hum. Genet. 2:77-82
68. Kan YW, Dozy AM. 1978. Antenatal diagnosis of sickle-cell anaemia by DNA analysis of amniotic-fluid cells. Lancet 2:910-12
69. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, et al. 1996. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2:405-11
70. Kato H, Tsuchiya N, Izumi S, Miyamasu M, Nakajima T, et al. 1999. New variations of human CC-chemokine receptors CCR3 and CCR4. Genes Immun. 1:97-104
71. Keet IP, Klein MR, Just JJ, Kaslow RA. 1996. The role of host genetics in the natural history of HIV-1 infection: The needles in the haystack. AIDS 10:S59-67
72. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, et al. 2001. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193:375-86
73. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, et al. 1989. Identification of the cystic fibrosis gene: Genetic analysis. Science 245:1073-80
74. Khomenko AG, Litvinov VI, Chukanova VP, Pospelov LE. 1990. Tuberculosis in patients with various HLA phenotypes. Tubercle 71:187-92
75. Klein J. 1986. Natural History of the Major Histocompatibility Complex. New York: Wiley. 775 pp.
76. Klein J. 1987. Origin of major histocompatibility complex polymorphism: The trans-species hypothesis. Hum. Immunol. 19:155-62
77. Klein MR, Keet IP, D'Amaro J, Bende RJ, Hekman A, et al. 1994. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men. J. Infect. Dis. 169:1244-49
78. Klitz W, Brautbar C, Schito AM, Barcellos LF, Oksenberg JR. 2001. Evolution of the CCR5-? 32 mutation based on haplotype variation in Jewish and Northem European population samples. Hum. Immunol. 62:530-38
79. Kostrikis LG, Huang Y, Moore JP, Wolinsky SM, Zhang L, et al. 1998. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat. Med. 4:350-53
80. Liao F, Alkhatib G, Peden KW, Sharma G, Berger EA, Farber JM. 1997. STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J. Exp. Med. 185:2015-23
81. Libert F, Cochaux P, Beckman G, Samson M, Aksenova M, et al. 1998. The delta-ccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum. Mol. Genet. 7:399-406
82. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, et al. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 86:367-77
83. Liu R, Zhao X, Gurney TA, Landau NR. 1998. Functional analysis of the proximal CCR5 promoter. AIDS 14:1509-19
84. Locati M, Murphy PM. 1999. Chemokines and chemokine receptors: Biology and clinical relevance in inflammation and AIDS. Annu. Rev. Med. 50:425-40
85. Lucotte G, Mercier G. 1998. Distribution of the CCR5 gene 32-bp deletion in Europe. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 19:174-77
86. Lucotte G, Mercier G, Smets P. 1999. Elevated frequencies of the mutant allele delta32 at the CCR5 gene in Ashkenazic Jews. AIDS 15:1-2
87. MacDonald KS, Embree J, Njenga S, Nagelkerke NJ, Ngatia I, et al. 1998. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. J. Infect. Dis. 177:551-56
88. MacDonald KS, Embree JE, Nagelkerke NJ, Castillo J, Ramhadin S, et al. 2001. The HLA A2/6802 supertype is associated with reduced risk of perinatal human immunodeficiency virus type 1 transmission. J. Infect. Dis. 183:503-6
89. MacDonald KS, Fowke KR, Kimani J, Dunand VA, Nagelkerke NJ, et al. 2000. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J. Infect. Dis. 181:1581-89
90. Maho A, Bensimon A, Vassart G, Parmentier M. 1999. Mapping of the CCXCR1, CX3CR1, CCBP2, and CCR9 genes to the CCR cluster within the 3p21.3 region of the human genome. Cytogenet. Cell Genet. 87:265-68
91. Martin K, Heinzlmann M, Borchers R, Mack M, Loeschke K, Folwaczny C. 2001. Delta32 mutation of the chemokine-receptor 5 gene in inflammatory bowel disease. Clin. Immunol. 98:18-22
92. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, et al. 1998. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282:1907-11
93. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. 1997. Global distribution of the CCR5 gene 32-basepair deletion. Nat. Genet. 16:100-3
94. Martinson JJ, Hong L, Karanicolas R, Moore JP, Kostrikis LG. 2000. Global distribution of the CCR2-64I/CCR5-59653T HIV-1 disease-protective haplotype. AIDS 14:483-89
95. McDermott DH, Beecroft MJ, Kleeberger CA, Al-Sharif FM, Ollier WE, et al. 2000. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS 14:2671-78
96. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. 1998. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 352:866-70
97. Mellado M, Rodriguez-Frade JM, VilaCoro AJ, de Ana AM, Martinez AC. 1999. Chemokine control of HIV-1 infection. Nature 400:723-24
98. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, et al. 2000. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long-term nonprogressors. Proc. Natl. Acad. Sci. USA 97:2709-14
99. Miller LH, Mason SJ, Clyde DF, McGinniss MH. 1976. The resistance factor to Plasmodium vivax in blacks. The Duffyblood-group genotype, FyFy. N. Engl. J. Med. 295:302-4
100. Minton EJ, Smillie D, Neal KR, Irving WL, Underwood JC, James V. 1998. Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group. J. Infect. Dis. 178:39-44
101. Mitchell TJ, Walley AJ, Pease JE, Venables PJ, Wiltshire S, et al. 2000. Delta 32 deletion of CCR5 gene and association with asthma or atopy. Lancet 356:1491-92
102. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, et al. 1998. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat. Med. 4:786-93
103. Mummidi S, Ahuja SS, McDaniel BL, Ahuja SK. 1997. The human CC chemokine receptor 5 (CCR5) gene. Multiple transcripts with 5′ end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons. J. Biol. Chem. 272:30662-71
104. Nguyen GT, Carrington M, Beeler JA, Dean M, Aledort LM, et al. 1999. Phenotypic expressions of CCR5-delta32/delta32 homozygosity. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 22:75-82
105. Nowak MA, Anderson RM, McLean AR, Wolfs TF, Goudsmit J, May RM. 1991. Antigenic diversity thresholds and the development of AIDS. Science 254:963-69
106. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, et al. 1996. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382:833-35
107. O'Brien SJ. 1991. Ghetto legacy. Curr. Biol. 4:209-11
108. O'Brien SJ, Mann, DL. 1992. Adoptive chaos and AIDS. Curr. Biol. 2:203-5
109. O'Brien SJ, Moore JP. 2000. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol. Rev. 177:99-111
110. O'Brien SJ, Nelson GW, Winkler CA, Smith MW. 2000. Polygenic and multifactorial disease gene association in man: Lessons from AIDS. Annu. Rev. Genet. 34:563-91
111. O'Brien SJ, Roelke ME, Marker L, Newman A, Winkler CA, et al. 1985. Genetic basis for species vulnerability in the cheetah. Science 227:1428-34
112. Parham P, Adams EJ, Arnett KL. 1995. The origins of HLA-A,B,C polymorphism. Immunol. Rev. 143:141-80
113. Parham P, Ohta T. 1996. Population biology of antigen presentation by MHC class I molecules. Science 272:67-74
114. Petrek M, Drabek J, Kolek V, Zlamal J, Welsh KI, et al. 2000. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 162:1000-3
115. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, et al. 1991. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453-59
116. Pier GB, Grout M, Zaidi T, Meluleni G, Mueschenbom SS, et al. 1998. Salmonella typhi uses CFTR to enter intestinal epithelial cells. Nature 393:79-82
117. Potts WK, Slev PR. 1995. Pathogen-based models favoring MHC genetic diversity. Immunol. Rev. 143:181-97
118. Quillent C, Oberlin E, Braun J, Rousset D, Gonzalez-Canali G, et al. 1998. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 351:14-18
119. Rector A, Vermeire S, Thoelen I, Keyaerts E, Struyf R, et al. 2001. Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease. Hum. Genet. 108:190-93
120. Rollins BJ. 1997. Chemokines. Blood 90:909-28
121. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, et al. 1995. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1:59-64
122. Sahmoud T, Laurian Y, Gazengel C, Sultan Y, Gautreau C, Costagliola D. 1993. Progression to AIDS in French hemophiliacs: Association with HLA-B35. AIDS 7:497-500
123. Salemi M, Strimmer K, Hall WW, Duffy M, Delaporte E, et al. 2001. Dating the common ancestor of SIVcpz and HIV-1 group M and the origin of HIV-1 subtypes using a new method to uncover clock-like molecular evolution. FASEB J. 15:276-78
124. Salvarani C, Boiardi L, Timms JM, Silvestri T, Ranzi A, et al. 2000. Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica. Clin. Exp. Rheumatol. 18:591-95
125. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, et al. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-25
126. a. Sanford AJ, Zhu S, Bai TR, Fitzgerald JM, Pare PD. 2001. The role of the CC chemokine receptor-5 Delta32 polymorphism in asthma and in the production of regulated-on-activation normal T cells expressed and secreted. J. Allergy Clin. Immunol. 108:69-73
127. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P. 2000. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J. Neuroimmunol. 102:98-106
128. Shiga H, Shioda T, Tomiyama H, Takamiya Y, Oka S, et al. 1996. Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human leukocyte antigen B35 molecules. AIDS 10:1075-83
129. Shin HD, Winkler C, Stephens JC, Bream J, Young H, et al. 2000. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc. Natl. Acad. Sci. USA 97:14467-72
130. Sidney J, Grey HM, Kubo RT, Sette A. 1996. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol. Today 17:261-66
131. Sidney J, Grey HM, Southwood S, Celis E, Wentworth PA, et al. 1996. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum. Immunol. 45:79-93
132. Singh SP, Mehra NK, Dingley HB, Pande JN, Vaidya MC. 1983. Human leukocyte antigen (HLA)-linked control of susceptibility to pulmonary tuberculosis and association with HLA-DR types. J. Infect. Dis. 148:676-81
133. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, et al. 1997. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 277:959-65
134. Stephens JC, Reich DE, Goldstein DB, Shin HD, Smith MW, et al. 1998. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am. J. Hum. Genet. 62:1507-15
135. Szalai C, Csaszar A, Czinner A, Szabo T, Panczel P, et al. 1999. Chemokine receptor CCR2 and CCR5 polymorphisms in children with insulin-dependent diabetes mellitus. Pediatr. Res. 46:82-84
136. Takahata N, Nei M. 1990. Allelic genealogy under overdominant and frequency-dependent selection and polymorphism of major histocompatibility complex loci. Genetics 124:967-78
137. Tang J, Costello C, Keet IP, Rivers C, Leblanc S, et al. 1999. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS 15:317-24
138. Thio CL, Thomas DL, Carrington M. 2000. Chronic viral hepatitis and the human genome. Hepatology 31:819-27
139. Thio CL, Thomas DL, Goedert JJ, Vlahov D, Nelson KE, et al. 2001. Racial differences in HLA class II associations with hepatitus C virus outcomes. J. Infect. Dis. 184:16-21
140. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. 1999. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Hepatitis C European Network for Cooperative Research. Lancet 354:2119-24
141. Thursz MR, Kwiatkowski D, Allsopp CE, Greenwood BM, Thomas HC, Hill AV. 1995. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N. Engl. J. Med. 332:1065-69
142. Thursz MR, Thomas HC, Greenwood BM, Hill AV. 1997. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat. Genet. 17:11-12
143. Todd JR, West BC, McDonald JC. 1990. Human leukocyte antigen and leprosy: Study in northern Louisiana and review. Rev. Infect. Dis. 12:63-74
144. Tomiyama H, Miwa K, Shiga H, Moore YI, Oka S, et al. 1997. Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS. J. Immunol. 158:5026-34
145. Tsui LC. 1995. The cystic fibrosis transmembrane conductance regulator gene. Am. J. Respir. Crit. Care Med. 151:S47-53
146. van Eden W, de Vries RR, Mehra NK, Vaidya MC, D'Amaro J, van Rood JJ. 1980. HLA segregation of tuberculoid leprosy: Confirmation of the DR2 marker. J. Infect. Dis. 141:693-701
147. Wang SS, Wheeler CM, Hildesheim A, Schiffman M, Herrero R, et al. 2001. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: Results from a population-based study in Costa Rica. J. Infect. Dis. 184:1310-14
148. Watkins DI, Hodi FS, Letvin NL. 1988. A primate species with limited major histocompatibility complex class I polymorphism. Proc. Natl. Acad. Sci. USA 85:7714-18
149. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, et al. 1998. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort. Science 279:389-93
150. Wright S. 1969. Evolution and the Genetics of Populations. Chicago: Univ. Chicago Press
151. Zhang YW, Ryder OA, Zhang YP. 1999. Sequence evolution of the CCR5 chemokine receptor gene in primates. Mol. Biol. Evol. 16:1145-54
152. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, et al. 1997. Inherited resistance to HIV-1 conferred by inactivating mutation in CC chemokine receptor 5: Studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol. Med. 3:23-26
153. Zinkernagel RM. 1996. Immunology taught by viruses. Science 271:173-78